Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 439

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 439
---
 June 2025, he served as the Chief Financial Officer of Cannible Foodtech Ltd. (CSE:PLCN). From March 2021 to February 2022, Uri Ben Or was the Chief Financial Officer of Nuvectis Pharma (NASDAQ: NVCT). From January 2018 to February 2022, Mr.Ben Or served as the Chief Financial Officer of Maayan Ventures Ltd. (TASE: MAYN). From October 2019 to January of 2020, Mr.Ben Or also served as the Chief Financial Officer of BiomX Inc. (NYSE American: PHGE). From October of 2001 to April 2014 he served as the Chief Financial Officer of Glycominds LLC. Mr.Ben -Orstarted his career as an Auditor at PwC Israel from May of 1997 until July of 1999. Mr.Ben -Orholds a B.A. degree in Business from the College of Management Academic Studies, Israel and an MBA from Bar -IlanUniversity, Israel. He is a Certified Public Accountant in Israel. Ariel Revel, MD, Director of Medical Affairs Professor Ariel Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served as a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a Professor of Medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009, and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April 2017 until April 2024, he served at the Assaf Harofeh Medical Center. On April 2017 until April 2021, he served as a Professor at Assaf Harofeh Medical Center. He began his medical career in August 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May 2017. Professor Revel received his PhD from Tel -AvivUniversity and an MD degree from the Hebrew University of Jerusalem, Israel. Eric Konofal, Chief Scientific Officer Eric Konofal, MD, Ph.D. has served as NLS’s Chief Scientific Officer since February 2021 and as its Interim Chief Medical Officer since January 2024. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal